With May being ALS Awareness Month comes the news of the beginning of testing an investigational treatment for the disease in healthy volunteer participants. NPT520-34 is an investigational small molecule that has shown to reduce levels of brain inflammation markers and central nervous system proteins of animal models of ALS, Alzheimer’s Disease and Parkinson’s disease. The interest in treating brain inflammation is due to it being a common feature amount many neurodegenerative disorders. Phase 1 trials with actual patients with neurodegenerative disorders may start as early as 2020.
Source:
https://alsnewstoday.com/2019/05/13/investigational-npt520-34-being-tested-healthy-volunteers-phase-1-trial/
